Evotec SE is to develop antisense oligonucleotide drugs for a number of indications under a new drug discovery collaboration with Secarna Pharmaceuticals GmbH of Munich, Germany. Secarna was founded in 2015 and has more than 15 programmes in development focusing on oncology, immunology, ophthalmology as well as cardiometabolic diseases.
The financial terms of the agreement were not disclosed. The agreement was announced on 5 August, only a week after Vico Therapeutics BV of the Netherlands raised $31 million for its preclinical antisense oligonucleotide platform.